Variceal Bleeding Management

Efficacy and Mechanism

Terlipressin, a synthetic analogue of vasopressin, reduces bleeding-related mortality compared to placebo (relative risk 0.66, 95% CI 0.49-0.88) 1
Terlipressin and octreotide, a somatostatin analogue, both reduce portal pressure by decreasing splanchnic blood flow 4
The American College of Radiology recommends the use of terlipressin or octreotide to reduce portal pressure 4

The initial dose of terlipressin is 2 mg IV every 4 hours for the first 48 hours until bleeding is controlled 1
The maintenance dose of terlipressin is 1 mg IV every 4 hours for a total treatment duration of 2-5 days 1
Octreotide is administered as an initial IV bolus of 50 μg followed by continuous infusion of 50 μg/hour 2

The American College of Radiology recommends starting vasoactive agents as soon as variceal bleeding is suspected, even before endoscopic confirmation 1
Terlipressin is the preferred option when available due to its mortality benefit 1
Prophylactic antibiotics, such as IV ceftriaxone 1g daily, should be administered concurrently 6
Endoscopic therapy, preferably endoscopic variceal ligation, should be performed as soon as possible 6
The combination of endoscopic therapy plus vasoactive drugs is superior to either treatment alone 4

In patients with cardiac conditions or coronary artery disease, octreotide may be preferred due to fewer cardiovascular side effects 5
For patients with advanced cirrhosis or active bleeding despite vasoactive therapy, early TIPS placement should be considered 1
The Clinical and Molecular Hepatology society recommends considering octreotide in patients with cardiac conditions 5